What you should know:
1. The merger also included a funding round that raised $22 million.
2. The company is advancing two therapies: larazotide, a therapy for celiac disease currently in a phase 3 trial, and GLP-1, which treats short bowel syndrome.
3. John Temperato will lead a management team that has brought a combined 15 drugs to market.
More articles on surgery centers:
Life after ramp-up: How COVID-19 will change ASCs forever
3 ASC nurses join COVID-19 front lines in New York
4 hospitals, health systems opening ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.